JP2011504505A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011504505A5 JP2011504505A5 JP2010535073A JP2010535073A JP2011504505A5 JP 2011504505 A5 JP2011504505 A5 JP 2011504505A5 JP 2010535073 A JP2010535073 A JP 2010535073A JP 2010535073 A JP2010535073 A JP 2010535073A JP 2011504505 A5 JP2011504505 A5 JP 2011504505A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- nhc
- alkyl
- cooh
- cooet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 69
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 51
- 125000000623 heterocyclic group Chemical group 0.000 claims description 40
- 125000005843 halogen group Chemical group 0.000 claims description 39
- -1 thien Chemical compound 0.000 claims description 37
- 150000001875 compounds Chemical class 0.000 claims description 30
- 125000003277 amino group Chemical group 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 13
- 125000002837 carbocyclic group Chemical group 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 6
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 4
- 125000001963 4 membered heterocyclic group Chemical group 0.000 claims description 4
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims 33
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 21
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims 16
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 15
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 9
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 8
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 8
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 8
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims 8
- SLLFVLKNXABYGI-UHFFFAOYSA-N 1,2,3-benzoxadiazole Chemical compound C1=CC=C2ON=NC2=C1 SLLFVLKNXABYGI-UHFFFAOYSA-N 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 7
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 6
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 claims 6
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 6
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 6
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 6
- 125000002252 acyl group Chemical group 0.000 claims 6
- 125000004442 acylamino group Chemical group 0.000 claims 6
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 6
- 125000002619 bicyclic group Chemical group 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 6
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 6
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 claims 6
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 6
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 5
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 5
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 5
- LYKMMUBOEFYJQG-UHFFFAOYSA-N piperoxan Chemical compound C1OC2=CC=CC=C2OC1CN1CCCCC1 LYKMMUBOEFYJQG-UHFFFAOYSA-N 0.000 claims 5
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims 5
- 150000003852 triazoles Chemical class 0.000 claims 5
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 4
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 claims 4
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 4
- 125000006164 6-membered heteroaryl group Chemical group 0.000 claims 4
- 206010063057 Cystitis noninfective Diseases 0.000 claims 4
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 4
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 4
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 4
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 150000003536 tetrazoles Chemical class 0.000 claims 4
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims 3
- DGCOGZQDAXUUBY-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole Chemical class C1=CC=C2OC(F)(F)OC2=C1 DGCOGZQDAXUUBY-UHFFFAOYSA-N 0.000 claims 3
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 claims 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 3
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 3
- 125000003368 amide group Chemical group 0.000 claims 3
- 125000004103 aminoalkyl group Chemical group 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 125000005111 carboxyalkoxy group Chemical group 0.000 claims 3
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 3
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims 2
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims 2
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 claims 2
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 claims 2
- FVYFYUSRNVYACL-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine-2,3-dione Chemical compound C1=CN=C2C(=O)C(=O)NC2=C1 FVYFYUSRNVYACL-UHFFFAOYSA-N 0.000 claims 2
- FPEXZUSKGJEHCF-UHFFFAOYSA-N 2,3,5-trioxabicyclo[2.2.2]octane Chemical compound O1CC2CCC1OO2 FPEXZUSKGJEHCF-UHFFFAOYSA-N 0.000 claims 2
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims 2
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 claims 2
- LJRXNXBFJXXRNQ-UHFFFAOYSA-N 2h-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC=CN2C(=O)NN=C21 LJRXNXBFJXXRNQ-UHFFFAOYSA-N 0.000 claims 2
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 claims 2
- YCIPQJTZJGUXND-UHFFFAOYSA-N Aglaia odorata Alkaloid Natural products C1=CC(OC)=CC=C1C1(C(C=2C(=O)N3CCCC3=NC=22)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 YCIPQJTZJGUXND-UHFFFAOYSA-N 0.000 claims 2
- 206010065687 Bone loss Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 claims 2
- 206010037211 Psychomotor hyperactivity Diseases 0.000 claims 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims 2
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims 2
- 125000004945 acylaminoalkyl group Chemical group 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 2
- 125000000676 alkoxyimino group Chemical group 0.000 claims 2
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 2
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 claims 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 2
- 230000001548 androgenic effect Effects 0.000 claims 2
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims 2
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 claims 2
- 125000005110 aryl thio group Chemical group 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims 2
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 claims 2
- 239000012964 benzotriazole Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 2
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 claims 2
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 125000004984 dialkylaminoalkoxy group Chemical group 0.000 claims 2
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 2
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 claims 2
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 claims 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 2
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims 2
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 claims 2
- CNMOHEDUVVUVPP-UHFFFAOYSA-N piperidine-2,3-dione Chemical compound O=C1CCCNC1=O CNMOHEDUVVUVPP-UHFFFAOYSA-N 0.000 claims 2
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims 2
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 claims 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 2
- QFYXSLAAXZTRLG-UHFFFAOYSA-N pyrrolidine-2,3-dione Chemical compound O=C1CCNC1=O QFYXSLAAXZTRLG-UHFFFAOYSA-N 0.000 claims 2
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 claims 2
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 229930192474 thiophene Natural products 0.000 claims 2
- OVCXRBARSPBVMC-UHFFFAOYSA-N triazolopyridine Chemical compound C=1N2C(C(C)C)=NN=C2C=CC=1C=1OC=NC=1C1=CC=C(F)C=C1 OVCXRBARSPBVMC-UHFFFAOYSA-N 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 claims 1
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 claims 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 1
- BXDFRTXDYDCALN-UHFFFAOYSA-N 2-(azetidin-1-yl)pyridine Chemical compound C1CCN1C1=CC=CC=N1 BXDFRTXDYDCALN-UHFFFAOYSA-N 0.000 claims 1
- HWKKEILUSBLEOI-UHFFFAOYSA-N 2-(azetidin-1-yl)pyrimidine Chemical compound C1CCN1C1=NC=CC=N1 HWKKEILUSBLEOI-UHFFFAOYSA-N 0.000 claims 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 claims 1
- YSGASDXSLKIKOD-UHFFFAOYSA-N 2-amino-N-(1,2-diphenylpropan-2-yl)acetamide Chemical compound C=1C=CC=CC=1C(C)(NC(=O)CN)CC1=CC=CC=C1 YSGASDXSLKIKOD-UHFFFAOYSA-N 0.000 claims 1
- AJEUJXWLOADTKA-UHFFFAOYSA-N 2-piperidin-1-ylpyridine Chemical compound C1CCCCN1C1=CC=CC=N1 AJEUJXWLOADTKA-UHFFFAOYSA-N 0.000 claims 1
- IAGROJPXACRRDT-UHFFFAOYSA-N 2-piperidin-1-ylpyrimidine Chemical compound C1CCCCN1C1=NC=CC=N1 IAGROJPXACRRDT-UHFFFAOYSA-N 0.000 claims 1
- UTYDSRLFMRPPHP-UHFFFAOYSA-N 2-pyridin-4-yl-1,3,4-oxadiazole Chemical class O1C=NN=C1C1=CC=NC=C1 UTYDSRLFMRPPHP-UHFFFAOYSA-N 0.000 claims 1
- AZYTZQYCOBXDGY-UHFFFAOYSA-N 2-pyrrolidin-1-ylpyridine Chemical compound C1CCCN1C1=CC=CC=N1 AZYTZQYCOBXDGY-UHFFFAOYSA-N 0.000 claims 1
- PCXCZMYBFGWKKH-UHFFFAOYSA-N 2-pyrrolidin-1-ylpyrimidine Chemical compound C1CCCN1C1=NC=CC=N1 PCXCZMYBFGWKKH-UHFFFAOYSA-N 0.000 claims 1
- MESFXNGUDNODTJ-UHFFFAOYSA-N 2h-thiazine 1,1-dioxide Chemical compound O=S1(=O)NC=CC=C1 MESFXNGUDNODTJ-UHFFFAOYSA-N 0.000 claims 1
- VTUKKVHSZDBIPA-UHFFFAOYSA-N 3,5,8-trioxabicyclo[2.2.2]octane Chemical compound O1CC2COC1OC2 VTUKKVHSZDBIPA-UHFFFAOYSA-N 0.000 claims 1
- TZDKFMFJVGNYLS-UHFFFAOYSA-N 4-(1h-pyrazol-4-yl)pyridine Chemical class C1=NNC=C1C1=CC=NC=C1 TZDKFMFJVGNYLS-UHFFFAOYSA-N 0.000 claims 1
- BADSZRMNXWLUKO-UHFFFAOYSA-N 4-chloro-1h-pyrazole Chemical class ClC=1C=NNC=1 BADSZRMNXWLUKO-UHFFFAOYSA-N 0.000 claims 1
- PYXNITNKYBLBMW-UHFFFAOYSA-N 5-(trifluoromethyl)-1h-pyrazole Chemical compound FC(F)(F)C1=CC=NN1 PYXNITNKYBLBMW-UHFFFAOYSA-N 0.000 claims 1
- YBZAPCTXZPUFPS-UHFFFAOYSA-N 5-pyridin-4-yl-1,2,4-oxadiazole Chemical class C1=NOC(C=2C=CN=CC=2)=N1 YBZAPCTXZPUFPS-UHFFFAOYSA-N 0.000 claims 1
- AULWPXHFRBLPAE-UHFFFAOYSA-N 6-chloropyridine Chemical class ClC1=C=CC=C[N]1 AULWPXHFRBLPAE-UHFFFAOYSA-N 0.000 claims 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 1
- KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 claims 1
- 229940121926 Calpain inhibitor Drugs 0.000 claims 1
- 102100035037 Calpastatin Human genes 0.000 claims 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims 1
- ZQPQGKQTIZYFEF-WCVJEAGWSA-N Huperzine Natural products C1([C@H]2[C@H](O)C(=O)N[C@H]2[C@@H](O)C=2C=CC=CC=2)=CC=CC=C1 ZQPQGKQTIZYFEF-WCVJEAGWSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical group Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- 241001024304 Mino Species 0.000 claims 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 claims 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 108010079785 calpain inhibitors Proteins 0.000 claims 1
- 108010044208 calpastatin Proteins 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 150000001733 carboxylic acid esters Chemical class 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 235000017471 coenzyme Q10 Nutrition 0.000 claims 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims 1
- 229940110767 coenzyme Q10 Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229960003530 donepezil Drugs 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 claims 1
- 150000002475 indoles Chemical class 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 1
- 229960004640 memantine Drugs 0.000 claims 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical group CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 1
- OGZQTTHDGQBLBT-UHFFFAOYSA-N neramexane Chemical compound CC1(C)CC(C)(C)CC(C)(N)C1 OGZQTTHDGQBLBT-UHFFFAOYSA-N 0.000 claims 1
- 229950004543 neramexane Drugs 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 150000003138 primary alcohols Chemical class 0.000 claims 1
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 claims 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 claims 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims 1
- 150000007660 quinolones Chemical class 0.000 claims 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 claims 1
- 229950000659 remacemide Drugs 0.000 claims 1
- 150000003333 secondary alcohols Chemical class 0.000 claims 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 claims 1
- 125000001174 sulfone group Chemical group 0.000 claims 1
- 125000003375 sulfoxide group Chemical group 0.000 claims 1
- 229960001685 tacrine Drugs 0.000 claims 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims 1
- 150000003509 tertiary alcohols Chemical class 0.000 claims 1
- 150000003512 tertiary amines Chemical class 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 0 CC(*)N1C=NC2C(*)=NC(N)=NC12 Chemical compound CC(*)N1C=NC2C(*)=NC(N)=NC12 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZPAWNIGEGKPSGI-UHFFFAOYSA-N CC(C)(C=CC=C1S(N2)(O)O)C=C1C2=O Chemical compound CC(C)(C=CC=C1S(N2)(O)O)C=C1C2=O ZPAWNIGEGKPSGI-UHFFFAOYSA-N 0.000 description 1
- KEXUANWSSZLZLM-UHFFFAOYSA-N CC(C=C1O2)=CCC1OC2(F)F Chemical compound CC(C=C1O2)=CCC1OC2(F)F KEXUANWSSZLZLM-UHFFFAOYSA-N 0.000 description 1
- GQXNITMWPPONCD-UHFFFAOYSA-N CN(CC1)CCN1C(NC[Cs])=O Chemical compound CN(CC1)CCN1C(NC[Cs])=O GQXNITMWPPONCD-UHFFFAOYSA-N 0.000 description 1
- IRVXVQCPGOTISD-UHFFFAOYSA-N CN1C(N)=CC=C/C1=[O]/c(cc1)cc(C(N2CS=C)=O)c1S2(O)O Chemical compound CN1C(N)=CC=C/C1=[O]/c(cc1)cc(C(N2CS=C)=O)c1S2(O)O IRVXVQCPGOTISD-UHFFFAOYSA-N 0.000 description 1
- FALGRFORCYCYQH-UHFFFAOYSA-N CSC(C=C1)=NNC1=O Chemical compound CSC(C=C1)=NNC1=O FALGRFORCYCYQH-UHFFFAOYSA-N 0.000 description 1
- GYPMBQZAVBFUIZ-UHFFFAOYSA-N Cc(cc1OC)ccc1OC Chemical compound Cc(cc1OC)ccc1OC GYPMBQZAVBFUIZ-UHFFFAOYSA-N 0.000 description 1
- KKFDCBRMNNSAAW-UHFFFAOYSA-N OCCN1CCOCC1 Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
- IUDUFNIFPSKLBK-UHFFFAOYSA-N SOCCN1CCCC1 Chemical compound SOCCN1CCCC1 IUDUFNIFPSKLBK-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98955107P | 2007-11-21 | 2007-11-21 | |
| PCT/US2008/084230 WO2009067621A1 (en) | 2007-11-21 | 2008-11-20 | Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014209336A Division JP2015044829A (ja) | 2007-11-21 | 2014-10-10 | 肺疾患及び心臓血管疾患を治療するためのビアリールｐｄｅ４阻害薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011504505A JP2011504505A (ja) | 2011-02-10 |
| JP2011504505A5 true JP2011504505A5 (enExample) | 2014-05-29 |
Family
ID=40376234
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010535073A Pending JP2011504505A (ja) | 2007-11-21 | 2008-11-20 | 肺および心血管障害を治療するためのビアリールｐｄｅ４抑制剤 |
| JP2014046962A Withdrawn JP2014185149A (ja) | 2007-11-21 | 2014-03-10 | 炎症を治療するためのビアリールｐｄｅ４阻害薬 |
| JP2014209336A Withdrawn JP2015044829A (ja) | 2007-11-21 | 2014-10-10 | 肺疾患及び心臓血管疾患を治療するためのビアリールｐｄｅ４阻害薬 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014046962A Withdrawn JP2014185149A (ja) | 2007-11-21 | 2014-03-10 | 炎症を治療するためのビアリールｐｄｅ４阻害薬 |
| JP2014209336A Withdrawn JP2015044829A (ja) | 2007-11-21 | 2014-10-10 | 肺疾患及び心臓血管疾患を治療するためのビアリールｐｄｅ４阻害薬 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US20090324569A1 (enExample) |
| EP (3) | EP2222639A1 (enExample) |
| JP (3) | JP2011504505A (enExample) |
| KR (2) | KR20100098653A (enExample) |
| CN (2) | CN102026970B (enExample) |
| AU (1) | AU2008326309C1 (enExample) |
| CA (1) | CA2722611A1 (enExample) |
| IL (1) | IL205882A0 (enExample) |
| WO (1) | WO2009067621A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2251867B1 (es) * | 2004-06-21 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| ES2320954B1 (es) * | 2007-03-02 | 2010-03-16 | Laboratorio Almirall S.A. | Nuevo procedimiento de preparacion de 3-metil-4-fenilisoxazolo (3,4-d)iridazin-7(6h)-ona. |
| EP2222638A2 (en) * | 2007-11-21 | 2010-09-01 | Decode Genetics EHF | Biaryl pde4 inhibitors for treating inflammation |
| EP2222639A1 (en) * | 2007-11-21 | 2010-09-01 | Decode Genetics EHF | Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders |
| WO2010059838A2 (en) * | 2008-11-20 | 2010-05-27 | Decode Genetics Ehf | Pde4 inhibitors selective for the long form of pde4 for treating inflammation and avoiding side effects |
| CA2804593C (en) | 2010-07-09 | 2015-11-24 | Pfizer Limited | Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors |
| JP2013532185A (ja) | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 化合物 |
| WO2012007883A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain |
| ES2526981T3 (es) | 2010-07-12 | 2015-01-19 | Pfizer Limited | N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje |
| WO2012007877A2 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
| JP2013532184A (ja) | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 電位開口型ナトリウムチャネル阻害剤として有用なｎ−スルホニルベンズアミド誘導体 |
| US8865723B2 (en) | 2012-10-25 | 2014-10-21 | Tetra Discovery Partners Llc | Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury |
| US9073875B2 (en) | 2012-11-20 | 2015-07-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase |
| EP3345902B1 (en) | 2013-03-14 | 2019-10-30 | Dart Neuroscience (Cayman) Ltd. | Substituted pyridine and pyrazine compounds as pde4 inhibitors |
| TW201534301A (zh) * | 2013-08-16 | 2015-09-16 | Takeda Gmbh | 以組合療法治療認知損傷 |
| WO2015022418A1 (en) | 2013-08-16 | 2015-02-19 | Takeda Gmbh | Treatment of cognitive impairment with pde4 inhibitor |
| CN103588758A (zh) * | 2013-11-04 | 2014-02-19 | 南京大学 | 一类含1,4-苯并二噁烷骨架的硝基咪唑衍生物的合成、制备及其在抗癌药物中的应用 |
| SI3209655T1 (sl) | 2014-10-24 | 2020-11-30 | Landos Biopharma, Inc. | Terapevtiki na osnovi C-podobne lantionin sintetaze 2 |
| EA034912B1 (ru) * | 2015-06-03 | 2020-04-06 | Бристол-Маерс Сквибб Компани | 4-гидрокси-3-(гетероарил)пиридин-2-оновые агонисты apj для применения в лечении сердечно-сосудистых заболеваний |
| WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
| DE102016205102B4 (de) * | 2015-12-17 | 2022-01-05 | Robert Bosch Gmbh | Ventil in einer Hochdruckpumpe eines Kraftstoffeinspritzsystems und Hochdruckpumpe eines Kraftstoffeinspritzsystems mit diesem Ventil |
| EA202091325A1 (ru) | 2017-11-30 | 2020-08-28 | Лэндос Байофарма, Инк. | Способы лечения с помощью лигандов лантионин c-подобного белка 2 и подготовленных с их помощью клеток |
| WO2019119207A1 (en) * | 2017-12-18 | 2019-06-27 | Merck Sharp & Dohme Corp. | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
| CN110194744B (zh) * | 2018-02-26 | 2022-11-11 | 云南大学 | 一种抑制β-淀粉样蛋白生成的化合物及其制备方法和用途 |
| CN110194746B (zh) * | 2018-02-26 | 2022-11-18 | 云南大学 | 用于治疗阿尔茨海默症的化合物，其制备方法和用途 |
| CN110194743B (zh) * | 2018-02-26 | 2022-11-11 | 云南大学 | 苯基(3-甲氧基-4-(4-甲基-1h-咪唑-1-基)苯基)甲酮类化合物 |
| WO2019173613A1 (en) | 2018-03-07 | 2019-09-12 | Northwestern University | Substituted fused pyrrolo-diazepinones and uses thereof |
| WO2021127472A1 (en) | 2019-12-20 | 2021-06-24 | Landos Biopharma, Inc. | Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same |
| CN114057589B (zh) * | 2020-08-07 | 2025-05-23 | 上海再极医药科技有限公司 | 18f标记的联苯类化合物、其中间体、制备方法、药物组合物及应用 |
| US20240101552A1 (en) | 2020-09-18 | 2024-03-28 | Shanghai Pharmaceuticals Holding Co., Ltd. | Carbonyl heterocyclic compound and application thereof |
| JP2024502083A (ja) * | 2020-12-31 | 2024-01-17 | 清華大学 | ピリジン－２－アミン誘導体、その医薬組成物、及び使用 |
| CN116265440B (zh) * | 2021-12-16 | 2024-09-27 | 贵州大学 | 一种水杨酮拼接吡啶酮类化合物及其制备方法及应用 |
Family Cites Families (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2535015A (en) * | 1948-06-19 | 1950-12-19 | Dow Chemical Co | Diphenol compound composition for coccidiosis control |
| US3144479A (en) * | 1958-08-07 | 1964-08-11 | Chemie Linz Ag | New iodine-containing benzoic acid esters |
| US4287366A (en) * | 1980-03-10 | 1981-09-01 | Mitsui Toatsu Chemicals, Inc. | Process for preparing bisphenol sulfone derivatives |
| LU86387A1 (fr) * | 1986-04-04 | 1987-12-07 | Oreal | Composes aromatiques,leur procede de preparation et leur utilisation en medicine humaine et veterinaire et en cosmetique |
| DE3778430D1 (en) | 1986-06-20 | 1992-05-27 | Idemitsu Kosan Co | Polycarbonate. |
| EP0318492A1 (en) | 1986-08-11 | 1989-06-07 | Innovata Biomed Limited | Pharmaceutical formulations comprising microcapsules |
| US5179079A (en) | 1986-12-16 | 1993-01-12 | Novo Nordisk A/S | Nasal formulation and intranasal administration therewith |
| GB8723846D0 (en) | 1987-10-10 | 1987-11-11 | Danbiosyst Ltd | Bioadhesive microsphere drug delivery system |
| IT1223343B (it) | 1987-11-03 | 1990-09-19 | Also Lab Sas | Formulazioni farmaceutiche per somministrazione transdermica |
| US4994439A (en) | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
| CA2050905A1 (en) | 1989-02-23 | 1990-08-24 | George R. Felt | Therapeutic aerosol formulations |
| GB8921222D0 (en) | 1989-09-20 | 1989-11-08 | Riker Laboratories Inc | Medicinal aerosol formulations |
| US5292499A (en) | 1990-09-11 | 1994-03-08 | University Of Wales College Of Cardiff | Method of preparing medical aerosol formulations including drug dissolved in reverse micelles |
| US5230884A (en) | 1990-09-11 | 1993-07-27 | University Of Wales College Of Cardiff | Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations |
| GB9114760D0 (en) * | 1991-07-09 | 1991-08-28 | Pfizer Ltd | Therapeutic agents |
| US5237062A (en) * | 1992-04-28 | 1993-08-17 | Hay Allan S | Polymers derived from phenolphthaleins |
| JPH0624138A (ja) * | 1992-07-09 | 1994-02-01 | Hodogaya Chem Co Ltd | 感熱記録材料 |
| US6632456B1 (en) | 1993-06-24 | 2003-10-14 | Astrazeneca Ab | Compositions for inhalation |
| CA2144669A1 (en) | 1994-03-29 | 1995-09-30 | Kozo Akasaka | Biphenyl derivatives |
| IL114950A0 (en) | 1994-08-22 | 1995-12-08 | Hoechst Schering Agrevo Gmbh | Biphenyl derivatives and herbicidal agentd containing the same |
| US5707641A (en) | 1994-10-13 | 1998-01-13 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
| EP0793662A1 (en) * | 1994-11-23 | 1997-09-10 | Neurogen Corporation | Aminomethyl aryl compounds; dopamine receptor subtype selective ligands |
| US5594141A (en) * | 1994-11-23 | 1997-01-14 | Neurogen Corporation | Certain aminomethyl biphenyl, aminomethyl phenyl pyridine and aminomethyl phenyl pyrimidine derivatives; novel dopamine receptor subtype selective ligands |
| PL320458A1 (en) * | 1994-11-24 | 1997-09-29 | Hoffmann La Roche | Novel benzyl pyrimidines |
| US6524557B1 (en) | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
| CH689139A5 (de) | 1995-04-03 | 1998-10-30 | Cerbios Pharma Sa | Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung. |
| US6309671B1 (en) | 1995-04-14 | 2001-10-30 | Inhale Therapeutic Systems | Stable glassy state powder formulations |
| US5635161A (en) | 1995-06-07 | 1997-06-03 | Abbott Laboratories | Aerosol drug formulations containing vegetable oils |
| JPH11508264A (ja) * | 1995-06-23 | 1999-07-21 | メディケム リサーチ インコーポレイテッド | 抗ウィルス剤としてのビフラバノイドおよびその誘導体 |
| WO1997003967A1 (en) | 1995-07-22 | 1997-02-06 | Rhone-Poulenc Rorer Limited | Substituted aromatic compounds and their pharmaceutical use |
| US6120794A (en) | 1995-09-26 | 2000-09-19 | University Of Pittsburgh | Emulsion and micellar formulations for the delivery of biologically active substances to cells |
| EP0801557B1 (en) | 1995-10-12 | 2003-07-02 | Supergen, Inc. | Liposome formulations of 5beta steroids |
| DE19541146A1 (de) * | 1995-10-25 | 1997-04-30 | Schering Ag | Imidazolderivate und deren Verwendung als Stickstoffmonoxid-Synthase-Inhibitoren |
| GB9604926D0 (en) * | 1996-03-08 | 1996-05-08 | Sandoz Ltd | Organic compounds |
| WO1997036893A1 (en) * | 1996-03-29 | 1997-10-09 | Duphar International Research B.V. | Piperazine and piperidine compounds |
| FR2754260B1 (fr) * | 1996-10-04 | 1998-10-30 | Adir | Nouveaux derives substitues de biphenyle ou de phenylpyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JP3582936B2 (ja) * | 1996-07-10 | 2004-10-27 | 株式会社ノエビア | 皮膚外用剤 |
| FR2753706B1 (fr) * | 1996-09-20 | 1998-10-30 | Nouvelles amines cycliques n-substituees, leur procede de preparation et les compositions pharmaceutiques les renfermant | |
| TW486475B (en) * | 1996-12-26 | 2002-05-11 | Ube Industries | Acid addition salt of optically active piperidine compound and process for preparing the same |
| FR2762514B1 (fr) * | 1997-04-29 | 1999-10-22 | Sanofi Sa | Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation |
| EP0894794A1 (en) * | 1997-07-31 | 1999-02-03 | AESCULAPIUS FARMACEUTICI S.r.l. | Optical isomers of cloperastine |
| JP4321737B2 (ja) * | 1997-12-17 | 2009-08-26 | 塩野義製薬株式会社 | 新規ピリジン化合物 |
| CN1310612A (zh) | 1998-05-20 | 2001-08-29 | 利普索姆公司 | 新型颗粒制剂 |
| US6451349B1 (en) | 1998-08-19 | 2002-09-17 | Quadrant Healthcare (Uk) Limited | Spray-drying process for the preparation of microparticles |
| GB9814172D0 (en) | 1998-06-30 | 1998-08-26 | Andaris Ltd | Formulation for inhalation |
| AUPP494798A0 (en) | 1998-07-29 | 1998-08-20 | Pacific Biolink Pty Limited | Protective protein formulation |
| EP1112262B1 (en) * | 1998-09-09 | 2004-08-04 | Inflazyme Pharmaceuticals Ltd. | Substituted gamma-phenyl-delta-lactones and analogs thereof and uses related thereto |
| US6290987B1 (en) | 1998-09-27 | 2001-09-18 | Generex Pharmaceuticals, Inc. | Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids |
| US6294153B1 (en) | 1998-12-21 | 2001-09-25 | Generex Pharmaceuticals, Inc. | Aerosol pharmaceutical formulation for pulmonary and nasal delivery |
| US6436367B1 (en) | 1998-12-21 | 2002-08-20 | Generex Pharmaceuticals Inc. | Aerosol formulations for buccal and pulmonary application |
| EP1338272A1 (en) | 1998-12-21 | 2003-08-27 | Generex Pharmaceuticals Inc. | Aerosol formulations for buccal and pulmonary application comprising chenodeoxycholate or deoxycholate |
| KR100845769B1 (ko) | 1999-02-03 | 2008-07-11 | 파우더젝트 리서치 리미티드 | 하이드로겔 입자 제제 |
| AU2879100A (en) | 1999-02-12 | 2000-08-29 | Miles A. Libbey Iii | Formulation and system for intra-oral delivery of pharmaceutical agents |
| NZ513981A (en) | 1999-03-08 | 2004-02-27 | Powderject Res Ltd | Delivery of microparticle formulations using needleless syringe device for sustained-release of bioactive compounds |
| WO2000062759A1 (en) | 1999-04-16 | 2000-10-26 | Novo Nordisk A/S | Dry, mouldable drug formulation |
| EP1187639A1 (en) | 1999-06-04 | 2002-03-20 | Delrx Pharmaceutical Corporation | Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same |
| US20010036481A1 (en) | 1999-08-25 | 2001-11-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
| CA2382821A1 (en) | 1999-08-25 | 2001-03-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
| CA2383347A1 (en) | 1999-08-31 | 2001-03-08 | Maxia Pharmaceuticals, Inc. | Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes |
| EP1227086B1 (en) * | 1999-10-22 | 2006-03-29 | Takeda Pharmaceutical Company Limited | 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof |
| ES2220724T3 (es) | 2000-01-20 | 2004-12-16 | Basilea Pharmaceutica Ag | Composiciones de peptidos ciclicos administrables por via nasal. |
| US6221604B1 (en) * | 2000-02-07 | 2001-04-24 | Pe Corporation | Electron-deficient nitrogen heterocycle-substituted fluorescein dyes |
| EP1129705A1 (en) | 2000-02-17 | 2001-09-05 | Rijksuniversiteit te Groningen | Powder formulation for inhalation |
| US20050070578A1 (en) * | 2000-03-30 | 2005-03-31 | Baxter Anthony David | Small organic molecule regulators of cell proliferation |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| ATE364381T1 (de) | 2000-04-17 | 2007-07-15 | Vectura Ltd | Formulierungen zur verwendung in inhalationsvorrichtungen |
| GB0009468D0 (en) | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formulations for use in inhaler devices |
| US20020155084A1 (en) | 2000-06-02 | 2002-10-24 | The Regents Of The University Of The Michigan | Nanoemulsion formulations |
| AU2001290678A1 (en) | 2000-09-08 | 2002-03-22 | Powderject Research Limited | Alginate particle formulation |
| FI20002768L (fi) | 2000-12-18 | 2002-06-19 | Licentia Oy | Enteropäällysteisiä lääkekoostumuksia ja niiden valmistus |
| US6740666B2 (en) * | 2000-12-20 | 2004-05-25 | Merck & Co., Inc. | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| PL373912A1 (en) | 2001-03-07 | 2005-09-19 | Incyte San Diego, Inc. | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases |
| GB0107106D0 (en) | 2001-03-21 | 2001-05-09 | Boehringer Ingelheim Pharma | Powder inhaler formulations |
| CA2441733A1 (en) * | 2001-03-29 | 2002-10-10 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| US20030019437A1 (en) | 2001-07-26 | 2003-01-30 | John Fore | Ungulate game animal feed system and method |
| PT1418890E (pt) | 2001-08-16 | 2008-06-09 | Baxter Int | Formulações de micropartículas à base de propulsor |
| EP1456178A1 (en) * | 2001-12-21 | 2004-09-15 | Smithkline Beecham Plc | 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders |
| AU2003215334A1 (en) | 2002-02-22 | 2003-09-09 | Advanced Inhalation Research, Inc. | Inhalable formulations for sustained release |
| GB0205256D0 (en) * | 2002-03-06 | 2002-04-17 | Oxford Glycosciences Uk Ltd | Novel compounds |
| EP1487411B1 (en) | 2002-03-20 | 2019-01-02 | Civitas Therapeutics, Inc. | Inhalable sustained therapeutic formulations |
| EP1501822B1 (en) * | 2002-04-30 | 2010-12-15 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| AU2003233118B8 (en) | 2002-05-07 | 2009-07-30 | Ferring Bv | Desmopressin in an orodispersible dosage form |
| US6747048B2 (en) * | 2002-05-08 | 2004-06-08 | Bristol-Myers Squibb Company | Pyridine-based thyroid receptor ligands |
| JPWO2004007439A1 (ja) * | 2002-07-10 | 2005-11-10 | 住友製薬株式会社 | ビアリール誘導体 |
| EP1581535B3 (en) * | 2003-01-09 | 2009-09-02 | Astellas Pharma Inc. | Pyrrolopyridazine derivatives |
| ES2567571T3 (es) * | 2003-03-14 | 2016-04-25 | Astellas Pharma Inc. | Derivados de C-glucósido y sales de los mismos |
| CN1791580A (zh) | 2003-03-24 | 2006-06-21 | 麦克公司 | 联芳基取代的6元杂环钠通道阻滞剂 |
| CN1798738A (zh) | 2003-04-03 | 2006-07-05 | 麦克公司 | 作为钠通道阻滞剂的联芳基取代吡唑 |
| US7557143B2 (en) * | 2003-04-18 | 2009-07-07 | Bristol-Myers Squibb Company | Thyroid receptor ligands |
| DE602004031667D1 (de) | 2003-11-10 | 2011-04-14 | Merck & Co Inc | Substituierte trialzole als blocker des natriumkanals |
| CA2546601A1 (en) * | 2003-11-19 | 2005-06-09 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| BRPI0418148A (pt) * | 2003-12-25 | 2007-04-17 | Takeda Pharmaceutical | composto, prodroga de um composto, modulador da função do receptor gpr40, agente farmacêutico, uso de um composto e métodos de modificação de uma função do receptor gpr40 em um mamìfero, de profilaxia ou tratamento de diabetes em um mamìfero e de produção de um composto |
| KR20070004769A (ko) * | 2004-02-27 | 2007-01-09 | 암젠 인코포레이션 | 대사 장애의 치료에 사용되는 화합물, 약제학적 조성물 및그 사용방법 |
| HRP20120901T1 (hr) * | 2004-03-05 | 2012-12-31 | F. Hoffmann - La Roche Ag | Diaminopirimidini kao p2x3 i p2x2/3 |
| EP1726580A4 (en) * | 2004-03-15 | 2008-02-13 | Takeda Pharmaceutical | AMINOPHNYLPROPANO ACID DERIVATIVE |
| UY29016A1 (es) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
| CA2575808A1 (en) * | 2004-08-02 | 2006-02-16 | Osi Pharmaceuticals, Inc. | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds |
| CN100371324C (zh) | 2004-09-07 | 2008-02-27 | 天津大学 | 二烷基、二芳基四取代杂环化合物、其制备方法及其应用 |
| AP2007003980A0 (en) * | 2004-11-23 | 2007-06-30 | Pfizer Prod Inc | Dibenzylamine compounds and derivatives |
| KR101316992B1 (ko) | 2004-12-23 | 2013-10-11 | 갈데르마 리써어치 앤드 디벨로프먼트 | Ｒａｒ 수용체를 조절하는 신규 리간드, 및 인간 의학 및화장품에서의 그의 용도 |
| KR20070107022A (ko) | 2005-01-07 | 2007-11-06 | 신타 파마슈티칼스 코프. | 염증 및 면역 관련 용도를 위한 화합물 |
| RU2007148927A (ru) | 2005-05-26 | 2009-07-10 | Метабэйзис Терапьютикс, Инк. (Us) | Новые тиреомиметики, содержащие фосфиновую кислоту |
| JP2007063225A (ja) * | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| US20070078136A1 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US7723336B2 (en) * | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| WO2007039075A2 (en) * | 2005-09-29 | 2007-04-12 | Bayer Healthcare Ag | Pde inhibitors and combinations thereof for the treatment of urological disorders |
| JP2009531274A (ja) * | 2005-12-07 | 2009-09-03 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | キナーゼ阻害性ピロロピリジン化合物 |
| RU2008127253A (ru) * | 2005-12-08 | 2010-01-20 | Новартис АГ (CH) | 1,1,3-триоксо-1,2,5-тиадиазолидины и их применение в качестве ингибиторов птфаз |
| WO2007079186A2 (en) | 2005-12-30 | 2007-07-12 | Merck & Co., Inc. | 1, 3-oxazolidin-2-one derivatives useful as cetp inhibitors |
| WO2007123953A2 (en) * | 2006-04-19 | 2007-11-01 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
| TW200815377A (en) | 2006-04-24 | 2008-04-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
| USRE45336E1 (en) * | 2006-05-18 | 2015-01-13 | Arena Pharmaceuticals, Inc. | Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
| BRPI0711949A2 (pt) * | 2006-05-19 | 2012-01-17 | Taisho Pharmaceutical Co., Ltd. | composto c-fenil glicitol |
| EP2036887A1 (en) * | 2006-06-28 | 2009-03-18 | Sanwa Kagaku Kenkyusho Co., Ltd | Novel 6-5 bicycic heterocyclic derivative and medical use thereof |
| CN102516115B (zh) * | 2006-08-09 | 2016-05-11 | 史密丝克莱恩比彻姆公司 | 作为阿片样物质受体的拮抗剂或反向激动剂的新型化合物 |
| JP5231829B2 (ja) | 2007-02-15 | 2013-07-10 | 石原産業株式会社 | ピリジル−トリアゾロピリミジン誘導体又はその塩、それらを含有する有害生物防除剤並びにそれらの製造方法 |
| EP2132197A2 (en) * | 2007-03-21 | 2009-12-16 | Almirall, S.A. | Substituted pyrimidines as adenosine receptor antagonists |
| PE20090938A1 (es) * | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
| EP2222638A2 (en) | 2007-11-21 | 2010-09-01 | Decode Genetics EHF | Biaryl pde4 inhibitors for treating inflammation |
| JP5524853B2 (ja) | 2007-11-21 | 2014-06-18 | デコード ジェネティクス イーエイチエフ | 肺疾患及び心臓血管疾患を治療するための置換されたベンゾアゾールｐｄｅ４阻害剤 |
| US8877816B2 (en) * | 2007-11-21 | 2014-11-04 | Decode Genetics Ehf | 4-(or 5-) substituted catechol derivatives |
| EP2222639A1 (en) * | 2007-11-21 | 2010-09-01 | Decode Genetics EHF | Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders |
| FR2932180B1 (fr) | 2008-06-04 | 2012-08-10 | Centre Nat Rech Scient | Dihydro iso ca-4 et analogues : puissants cytotoxiques, inhibiteurs de la polymerisation de la tubuline |
| WO2010059838A2 (en) | 2008-11-20 | 2010-05-27 | Decode Genetics Ehf | Pde4 inhibitors selective for the long form of pde4 for treating inflammation and avoiding side effects |
| WO2010059836A1 (en) | 2008-11-20 | 2010-05-27 | Decode Genetics Ehf | Substituted aza-bridged bicyclics for cardiovascular and cns disease |
-
2008
- 2008-11-20 EP EP08852110A patent/EP2222639A1/en not_active Withdrawn
- 2008-11-20 EP EP13000717.2A patent/EP2674417A3/en not_active Withdrawn
- 2008-11-20 AU AU2008326309A patent/AU2008326309C1/en not_active Ceased
- 2008-11-20 JP JP2010535073A patent/JP2011504505A/ja active Pending
- 2008-11-20 CA CA2722611A patent/CA2722611A1/en not_active Abandoned
- 2008-11-20 KR KR1020107013784A patent/KR20100098653A/ko not_active Ceased
- 2008-11-20 WO PCT/US2008/084230 patent/WO2009067621A1/en not_active Ceased
- 2008-11-20 US US12/275,163 patent/US20090324569A1/en not_active Abandoned
- 2008-11-20 CN CN2008801251832A patent/CN102026970B/zh not_active Expired - Fee Related
- 2008-11-20 EP EP13000709.9A patent/EP2628727A3/en not_active Withdrawn
- 2008-11-20 US US12/275,152 patent/US20090136473A1/en not_active Abandoned
- 2008-11-20 KR KR1020107013786A patent/KR20100108346A/ko not_active Ceased
- 2008-11-20 CN CN201310270697XA patent/CN103351390A/zh active Pending
-
2010
- 2010-05-20 IL IL205882A patent/IL205882A0/en unknown
-
2012
- 2012-03-26 US US13/430,164 patent/US8791267B2/en not_active Expired - Fee Related
- 2012-04-27 US US13/457,716 patent/US20120213758A1/en not_active Abandoned
-
2014
- 2014-03-10 JP JP2014046962A patent/JP2014185149A/ja not_active Withdrawn
- 2014-06-23 US US14/311,728 patent/US20140301999A1/en not_active Abandoned
- 2014-10-10 JP JP2014209336A patent/JP2015044829A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011504505A5 (enExample) | ||
| JP2011505341A5 (enExample) | ||
| CN102026970B (zh) | 用于治疗肺部和心血管病症的联芳基pde4抑制剂 | |
| CN109790135B (zh) | 用于治疗或预防与痛风或高尿酸血症相关的症状的化合物、组合物和方法 | |
| JP2018519323A5 (enExample) | ||
| JP2019052178A (ja) | ブロモドメイン阻害剤としての新規の置換された二環式化合物 | |
| PT1992361E (pt) | Medicamento ou agente preventivo contra úlceras digestivas | |
| SK10197A3 (en) | Aromatic amino ethers, preparation methods thereof and pharmaceutical agents containing them | |
| CA2403514A1 (en) | 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors | |
| PT98438A (pt) | Processo de preparacao de compostos bis-aril biciclicos susbtituidos e de composicoes farmaceuticas que os contem | |
| JP2003513961A (ja) | シクロオキシゲナーゼ−２の阻害剤である５−アリール−１ｈ−１，２，４−トリアゾール化合物とそれを含む医薬品組成物 | |
| JP2013523792A (ja) | Ｐｄｅ４阻害剤及びｅｐ４受容体アンタゴニストを含有する医薬の組み合わせ | |
| JP2011504504A5 (enExample) | ||
| AU2009310807B2 (en) | Cyclohexane derivative and pharmaceutical use thereof | |
| JP2011519845A5 (enExample) | ||
| JP2006528624A (ja) | Ｐｄｅ４阻害剤として有用なニコチンアミド誘導体 | |
| JP2008533063A (ja) | ピリミジンカルボン酸誘導体およびそれらの使用 | |
| JP5893155B2 (ja) | Ｃｒｔｈ２受容体拮抗薬としての窒素含有縮合環式化合物 | |
| WO2016017699A1 (ja) | アゾールカルボン酸誘導体 | |
| US20130267711A1 (en) | Tricyclic compound | |
| KR101646180B1 (ko) | N-(5-아릴아미도-2-메틸페닐)-5-메틸이소옥사졸-4-카복스아미드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 fms 키나아제 저해제 | |
| HK40070781A (en) | Process for making deuterated hydroxy-benzbromarone and intermediates thereof | |
| HK40008772B (en) | Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia | |
| JPWO2001004110A1 (ja) | ベンズイミダゾール化合物 | |
| JPWO2022173795A5 (enExample) |